Sesen Bio, a small biotech firm whose investigational cancer treatment once seemed poised for approval, said Wednesday that it had withdrawn its application to market the drug in Europe.
The news follows the Food and Drug Administration’s decision to reject Sesen’s drug, called Vicineum, on Aug. 13. Last week, STAT reported that Sesen’s clinical trial in bladder cancer was marked by thousands of violations, investigator misconduct, and evidence of serious toxicity the company did not publicly disclose, according to hundreds of pages of internal documents.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
